Xpert® Xpress SARS-CoV-2 - FDA Emergency Use Authorization
4.9 (215) · € 14.00 · En Stock
.png)
Xpert® Xpress SARS-CoV-2/Flu/RSV received Emergency Use Authorization from the US FDA to support the global fight against COVID-19, with rapid detection of the current coronavirus SARS-CoV-2.
US FDA grants EUA for Cepheid's SARS-CoV-2 test
Cepheid on LinkedIn: Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2…
Xpert Xpress XPRSARS-COV2-10 Sars-CoV-2 Reagent Cartridge - Henry Schein Medical
FDA grants 'emergency use' coronavirus test that can deliver results in 45 minutes
QIAGEN - Diagnostic companies are stepping up together to
FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances - ScienceDirect
Cepheid on LinkedIn: Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2…
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test - COVID-19 - mobile.
New COVID-19 Rapid Diagnostic Approved On 'GeneXpert' TB Platform; Could Pave Way For More Testing In Low- & Middle-Income Countries - Health Policy Watch
covid-19
Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study - The Lancet Microbe
Cepheid Developing Combination Test for SARS-CoV-2, Flu A/B, and RSV
Frontiers Review of Current COVID-19 Diagnostics and Opportunities for Further Development
